Thiazolidinediones (TZDs) or peroxisome proliferator activated receptor γ (PPARγ) agonists such as pioglitazone, directly protect podocytes from injury as demonstrated in podocyte culture in vitro studies [1,2,3,4,5], and reduce proteinuria and glomerular injury in various animal models of glomerular disease, as reported in preclinical in vivo studies [5,6,7,8,9,10,11,12,13]. The gene discussed is PPARG; the disease is glomerular disorder.